期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

钙敏感受体激动剂的临床研究进展 被引量：9

下载PDF
导出
摘要 继发性甲状旁腺功能亢进症（SHPT）是慢性肾脏病（CKD）常见的并发症，慢性肾脏病导致患者矿物质和骨代谢异常，其严重性主要是导致心血管钙化，与透析患者的生存预后密切相关。活性维生素D类药物用于临床治疗继发性甲状旁腺功能亢进症常常伴发高血钙、高血磷而增加心血管钙化的危险。
作者 张凌 闫彩芸 张国锐
机构地区 中日友好医院肾内科
出处 《临床内科杂志》 CAS 2012年第5期295-298,共4页 Journal of Clinical Internal Medicine
基金 2010年北京市科委首都临床特色应用研究资助项目（D101100050010025）
关键词 钙敏感受体激动剂 西那卡塞
分类号 R977.7 [医药卫生—药品]
  • 相关文献

参考文献21

  • 1张训.慢性肾脏病继发性甲状旁腺功能亢进的新认识[J].中国中西医结合肾病杂志,2010,11(4):283-285. 被引量：15
  • 2王文博,张凌,笪冀平,卞维静,李文歌.继发性甲状旁腺功能亢进症患者维生素D受体和钙敏感受体的免疫组化研究[J].中国血液净化,2011,10(5):265-269. 被引量：14
  • 3Wada M, Furuya Y, Sakiyama J. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest, 1997,100 : 2977 -2983.
  • 4Antonsen JE, Sherrard D J, Andress DL, et al. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int, 1998,53:223-227.
  • 5Komaba H, Nakanishi S, Fujimori A, et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol,2010,12:2305-2314.
  • 6Komaba H, Nakanishi S, Fujimori A, et al. Cinaealeet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol,2010,5:2305-2314.
  • 7Block GA, Martin KJ, de Francisco AL, et al. Cinaealcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med, 2004,350 : 1516-1525.
  • 8Messa P, Macario F, Yaqoob M, et al. The OPTIMA study : assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol,2008 ,3 :36-45.
  • 9Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HC1 and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol,2008,3 : 1718-1325.
  • 10Strippoli GF,Tong A, Palmer SC, et al. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev ,2006,18 : CD006254.

二级参考文献21

  • 1Wetmore JB,Quades LD.Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease:time for a paradigm shift? Nat Clin Pract Nephrol,2009,5:24-33.
  • 2Liu S,Quarles LD.How fibroblast growth factor 23 works.J Am Soc Nephrol,2007,18(6):1637-1647.
  • 3Kuro-o M.Klotho in chronic kidney disease--what' s new?Nephrol Dial Transplant,2009,24(6):1705-1708.
  • 4Ketteler M,Biggar PH.As nature did not predict dialysis-what we can learn from FGF23 in end-stage renal disease? Nephrol Dial Transplant,2009,24(9):2618-2620.
  • 5Martin KI,Goldfarb S.Renal bone disease,disorders of divalent ions and nephrolithiasis NephSAP,2008,7:304-317.
  • 6Valle C,Rodriguez M,Santarnaria R,et al.Cinacalcet reduces the set point of the PTH-calcium curve.J Am Soc Nephrol,2008,19(12):2430-2436.
  • 7Messa P,Macário F,Yaqoob M,et al.The OPTIMA study:assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.Clin J Am Soc Nephrol,2008,3(1):36-45.
  • 8Fishbane S,Shapiro WB,Corry DB,et al.Cinacalcet HCI and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidisrn in dialysis patients compared with vitamin D alone:the ACHIEVE study results.Clin J Am Soc Nephrol,2008,3(6):1718-1725.
  • 9Strippoli GF,Palmer S,Tong A,et al.Meta-analysis of biochemical and patient-level effects of calcimimetic therapy.Am J Kidney Dis,2006,47(5):715-726.
  • 10Sprague SM,Evenepoel P,Curzi MP,et al.Simultaneous control of PTH and Ca×P Is sustained over three years of treatment with cinacalcet HC1.Clin J Am Soc Nephrol,2009,4(9):1465-1476.

共引文献26

同被引文献63

  • 1张凌,刘亚绵,卞维静,李程,赵丽,杜学海.化学性甲状旁腺切除术治疗慢性透析患者继发甲状旁腺功能亢进[J].中国血液净化,2002,1(2):31-35. 被引量：8
  • 2燕宇.西那卡塞的临床应用以及研究进展[J].中国血液净化,2012,11(8):460-463. 被引量：23
  • 3Dooley AC,Weiss NS,KestenbaumB.Increased risk of hip fracture among men with CKD[J].Am J Kidney Dis,2008,51:38-44.
  • 4Houillier P.Calcium-sensing in the kidney[J].Curr Opin Nephrol Hypertens,2013,22:566-571.
  • 5Nagano N.Pharmacological and clinical properties of calcimimetics:calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism[J].Pharmacol Ther,2006,109:339-365.
  • 6Nemeth EF,Heaton WH,Miller M,et al.Pharmacodynamics of the type Ⅱ calcimimetic compound cinacalcet HCl[J].J Pharmacol Exp Ther,2004,308:627-635.
  • 7Cunningham J,Floege J,London G,et al.Chnical outcomes in secondary hyperparathyroidism and the role of calcimimetics[J].NDT Plus One,2008:i29-35.
  • 8Valle C,Rodriguez M,Santamaria R,et al.Cinacalcet reduces the set point of the PTH calcium curve[J].J Am Soc Nephrol,2008,19:2430-2436.
  • 9Fishbane S,Shapiro WB,Corry DB,etal.Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone:the ACHIEVE study results[J].Clin J Am Soc Nephrol,2008,3:1718-1725.
  • 10Wetmore JB,Liu S,Krebill R,et al.Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD[J].Clin J Am Soc Nephrol,2010,5:110-116.

引证文献9

二级引证文献114

临床内科杂志
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部